Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome

Loading news article.

Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome | WAPE

Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome

Article summary

Related companies

Comments —